BMO Capital Initiates Coverage On BioMarin Pharmaceutical with Outperform Rating, Announces Price Target of $98

Benzinga Newsdesk www.benzinga.com Positive 65.7%

Neg 0% Neu 0% Pos 65.7%

BMO Capital analyst David Lebowitz initiates coverage on BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outperform rating and announces Price Target of $98.